Concord Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)
Concord Drugs Ltd · Outcome · 13 Nov 2026, 12:24 am
Concord Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 2,075 (+102.0% YoY | -0.9% QoQ) ■ EBITDA: 236 (+115.7% YoY | +3.6% QoQ) ■ EBITDA Margin (%): 11.4 (+73 bps YoY | +50 bps QoQ) ■ PAT: 110 (+471.0% YoY | -1.5% QoQ) ■ EPS (INR): 0.83 (+336.8% YoY | -2.4% QoQ)
Original exchange filing (PDF)
More announcements from Concord Drugs Ltd
- Board has approved and considered financial results for quarter ending 30th Sep, 2026. · 13 Nov 2026
- Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve Results for Quarter ending Sep 30, 2026. · 12 Nov 2026
- Annual general meeting -Scrutinizer''s Report · 01 Oct 2026
- Summary Proceedings of AGM · 01 Oct 2026
- Letter to members as per regulation 36(1)(b) · 08 Sept 2026
- Record date for Annual general meeting · 08 Sept 2026
- 31st Annual Report of the Company · 08 Sept 2026
- AGM to be held on 30.09.2026 at 09:00 AM · 08 Sept 2026
